FOLD vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
FOLD vs JNJ: Head-to-Head Comparison
This page compares Amicus Therapeutics, Inc. (FOLD) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.